{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:15:04Z","timestamp":1787004904683,"version":"build-2736575974"},"reference-count":57,"publisher":"Georg Thieme Verlag KG","issue":"10","funder":[{"name":"Forschungskommission of the Medical Faculty of the Heinrich Heine University","award":["29-2019"],"award-info":[{"award-number":["29-2019"]}]},{"name":"Forschungskommission of the Medical Faculty of the Heinrich Heine University","award":["18-2019"],"award-info":[{"award-number":["18-2019"]}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["PO 2247\/1-1"],"award-info":[{"award-number":["PO 2247\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["SFB1116"],"award-info":[{"award-number":["SFB1116"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background\u2003Transcatheter aortic valve implantation (TAVI) is an evolving treatment of severe aortic valve stenosis. However, thromboembolic events such as stroke are common, predominantly early after TAVI. Optimal periprocedural antithrombotic regime is unknown. Especially, as antithrombotic medication enhances bleeding risk, thrombin generation and platelet function are crucial in the pathogenesis of ischemic events. However, the impact of the TAVI procedure on thrombin formation and platelet reactivity is not known by now.<\/jats:p>\n                  <jats:p>Methods\u2003We evaluated thrombin levels using thrombin\u2013antithrombin (TAT) complexes and prothrombin fragments (PTFs) using enzyme-linked immunosorbent assay. Furthermore, platelet reactivity was measured via light transmission aggregometry before and 2\u2009hours after TAVI in 198 patients.<\/jats:p>\n                  <jats:p>Results\u2003TAT complexes and PTF F1\u2009+\u20092 substantially increased during TAVI. Postprocedurally, TAT complexes and PTF were significantly higher after TAVI compared with percutaneous coronary intervention due to acute myocardial infarction, while preprocedural TAT complexes and PTF F1\u2009+\u20092 did not differ. In contrast, platelet reactivity was not altered early after TAVI. Only adenosine diphosphate-induced aggregation was reduced, reflecting preprocedural loading with clopidogrel.<\/jats:p>\n                  <jats:p>Conclusion\u2003In this pilot study, we were able to demonstrate that thrombin generation is significantly increased early after TAVI, while platelet function is not affected. Increased thrombin concentrations may contribute to the high risk of postprocedural thromboembolic events. This leads to the hypothesis that extended peri-interventional anticoagulation early after TAVI may be an approach to reduce thromboembolic events.<\/jats:p>","DOI":"10.1055\/s-0041-1725190","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T20:07:46Z","timestamp":1616530066000},"page":"1310-1316","source":"Crossref","is-referenced-by-count":7,"title":["Impact of Transcatheter Aortic Valve Implantation on Thrombin Generation and Platelet Function"],"prefix":"10.1055","volume":"121","author":[{"given":"Philipp","family":"Mourikis","sequence":"first","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Dannenberg","sequence":"first","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Veulemans","sequence":"first","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Zako","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Helten","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"M\u2018Pembele","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Richter","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hohlfeld","sequence":"additional","affiliation":[{"name":"Institute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Zeus","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Kelm","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Polzin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.amjmed.2016.10.005","article-title":"Aortic stenosis: pathophysiology, diagnosis, and therapy","volume":"130","author":"J Joseph","year":"2017","journal-title":"Am J Med"},{"issue":"36","key":"ref2","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"H Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"issue":"14","key":"ref3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","article-title":"Surgical or transcatheter aortic-valve replacement in intermediate-risk patients","volume":"376","author":"M J Reardon","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"ref4","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"M J Mack","year":"2019","journal-title":"N Engl J Med"},{"issue":"04","key":"ref5","first-page":"e2494","article-title":"Exploring the difference in post-procedural stroke rates between patients with aortic stenosis who undergo transcatheter aortic valve replacement versus surgical aortic valve replacement","volume":"10","author":"H Burke","year":"2018","journal-title":"Cureus"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/jcm8020280","article-title":"Thromboembolic and bleeding complications in transcatheter aortic valve implantation: insights on mechanisms, prophylaxis and therapy","volume":"8","author":"M P Ranasinghe","year":"2019","journal-title":"J Clin Med"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/JAHA.116.004203","article-title":"Neurological injury in intermediate-risk transcatheter aortic valve implantation","volume":"5","author":"J P Fanning","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"e022329","DOI":"10.1136\/bmjopen-2018-022329","article-title":"Silent cerebral infarction and cognitive function following TAVI: an observational two-centre UK comparison of the first-generation CoreValve and second-generation Lotus valve","volume":"9","author":"T A Musa","year":"2019","journal-title":"BMJ Open"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jcin.2013.10.016","article-title":"Usefulness of baseline activated clotting time-guided heparin administration in reducing bleeding events during transfemoral transcatheter aortic valve implantation","volume":"7","author":"C Bernelli","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","article-title":"Platelet thrombin receptor antagonism and atherothrombosis","volume":"31","author":"D J Angiolillo","year":"2010","journal-title":"Eur Heart J"},{"key":"ref11","first-page":"V13","article-title":"The role of platelets in acute vascular events","volume":"62","author":"L A Harker","year":"1980","journal-title":"Circulation"},{"issue":"13","key":"ref12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jacc.2012.01.001","article-title":"2012 ACCF\/AATS\/SCAI\/STS expert consensus document on transcatheter aortic valve replacement","volume":"59","author":"D R Holmes Jr","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of blood platelets by adenosine diphosphate and its reversal","volume":"194","author":"G V Born","year":"1962","journal-title":"Nature"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11239-015-1322-3","article-title":"Platelet reactivity in patients undergoing transcatheter aortic valve implantation","volume":"42","author":"K Orvin","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejphar.2015.01.028","article-title":"High on-treatment platelet reactivity in transcatheter aortic valve implantation patients","volume":"751","author":"A Polzin","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13216","article-title":"Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects","volume":"14","author":"L Traby","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcin.2018.10.005","article-title":"Assessment of platelet REACtivity After Transcatheter Aortic Valve Replacement: the REAC-TAVI trial","volume":"12","author":"V A Jimenez Diaz","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"15","key":"ref18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"J Brouwer","year":"2020","journal-title":"N Engl J Med"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1024\/0301-1526.32.4.193","article-title":"Thrombin-antithrombin complex and the prothrombin fragment in arterial and venous blood of patients with peripheral arterial disease","volume":"32","author":"J Hering","year":"2003","journal-title":"Vasa"},{"key":"ref20","first-page":"97","article-title":"Predictive role of coagulation, fibrinolytic, and endothelial markers in patients with atrial fibrillation, stroke, and thromboembolism: a meta-analysis, meta-regression, and systematic review","volume":"23","author":"A Weymann","year":"2017","journal-title":"Med Sci Monit Basic Res"},{"issue":"51","key":"ref21","doi-asserted-by":"crossref","first-page":"e13830","DOI":"10.1097\/MD.0000000000013830","article-title":"Coagulation markers and echocardiography predict atrial fibrillation, malignancy or recurrent stroke after cryptogenic stroke","volume":"97","author":"D Ellis","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jacc.2008.04.062","article-title":"Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study","volume":"52","author":"M R Di Tullio","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1160\/TH08-06-0398","article-title":"Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA","volume":"102","author":"I Fernandez-Cadenas","year":"2009","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00004872-199816040-00016","article-title":"Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men","volume":"16","author":"S Agewall","year":"1998","journal-title":"J Hypertens"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/j.1538-7836.2004.00993.x","article-title":"Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation","volume":"2","author":"M Barber","year":"2004","journal-title":"J Thromb Haemost"},{"key":"ref26","first-page":"216","article-title":"Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia study","volume":"28","author":"M L Bots","year":"1998","journal-title":"Haemostasis"},{"issue":"08","key":"ref27","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/j.1538-7836.2011.04403.x","article-title":"Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes","volume":"9","author":"T J Quinn","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"20","key":"ref28","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"J H Alexander","year":"2020","journal-title":"Circulation"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"832.e13","DOI":"10.1016\/j.jtcvs.2012.01.055","article-title":"Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial","volume":"143","author":"D C Miller","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1749-6632.2012.06477.x","article-title":"Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art","volume":"1254","author":"B G Hynes","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"25","key":"ref31","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1161\/CIRCULATIONAHA.112.110981","article-title":"Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation","volume":"126","author":"L Nombela-Franco","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jcin.2011.08.012","article-title":"A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation","volume":"4","author":"E L Tay","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"issue":"25","key":"ref33","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.jacc.2013.03.029","article-title":"Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events","volume":"62","author":"J Rod\u00e9s-Cabau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijcard.2017.01.088","article-title":"Impact of closure devices on vascular complication and mortality rates in TAVI procedures","volume":"241","author":"Z Dimitriadis","year":"2017","journal-title":"Int J Cardiol"},{"issue":"47","key":"ref35","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1093\/eurheartj\/ehv417","article-title":"Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation","volume":"36","author":"I M Barbash","year":"2015","journal-title":"Eur Heart J"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/ccd.28419","article-title":"Safety and efficacy of hybrid vascular closure technique using both a suture- and collagen-mediated closure device after transfemoral transcatheter aortic valve implantation","volume":"95","author":"A Al-Ani","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(18)30534-8","article-title":"Subclinical leaflet thrombosis","volume":"391","author":"K Piayda","year":"2018","journal-title":"Lancet"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1911426","article-title":"Reduced leaflet motion after transcatheter aortic-valve replacement","volume":"382","author":"O De Backer","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"ref39","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.jacc.2020.03.022","article-title":"Bioprosthetic aortic valve leaflet thickening in the evolut low risk sub-study","volume":"75","author":"P Blanke","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"G D Dangas","year":"2020","journal-title":"N Engl J Med"},{"issue":"09","key":"ref41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00392-018-1247-x","article-title":"NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation","volume":"107","author":"N A Geis","year":"2018","journal-title":"Clin Res Cardiol"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11239-019-01968-w","article-title":"Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry","volume":"50","author":"K Kalogeras","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.amjcard.2019.12.039","article-title":"Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists after transcatheter aortic valve implantation","volume":"125","author":"H Ueyama","year":"2020","journal-title":"Am J Cardiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ahj.2018.03.008","article-title":"Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial","volume":"200","author":"J P Collet","year":"2018","journal-title":"Am Heart J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2018.07.006","article-title":"Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial","volume":"205","author":"N M Van Mieghem","year":"2018","journal-title":"Am Heart J"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1055\/s-0040-1701206","article-title":"Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT trial","volume":"4","author":"P Kirchhof","year":"2020","journal-title":"TH Open"},{"issue":"06","key":"ref47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/07853890.2018.1495337","article-title":"Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA)","volume":"50","author":"K Miyazawa","year":"2018","journal-title":"Ann Med"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.thromres.2015.06.003","article-title":"Coagulation activation after discontinuation of VTE treatment with different oral anticoagulants and impact on 12-month clinical outcomes","volume":"136","author":"J Beyer-Westendorf","year":"2015","journal-title":"Thromb Res"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.joa.2016.07.011","article-title":"Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants","volume":"33","author":"T Nagao","year":"2017","journal-title":"J Arrhythm"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0038-1649561","article-title":"Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?","volume":"70","author":"S J Brister","year":"1993","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref51","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2009-05-222109","article-title":"Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation","volume":"114","author":"F Ni Ainle","year":"2009","journal-title":"Blood"},{"issue":"25","key":"ref52","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.jacc.2015.10.003","article-title":"Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: the randomized BRAVO-3 trial","volume":"66","author":"G D Dangas","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1213\/01.ane.0000278868.23814.3b","article-title":"Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin","volume":"105","author":"K A Tanaka","year":"2007","journal-title":"Anesth Analg"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2018.09.046","article-title":"Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention","volume":"171","author":"D Venetsanos","year":"2018","journal-title":"Thromb Res"},{"issue":"07","key":"ref55","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/2048872615592246","article-title":"Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial","volume":"6","author":"M V Madhavan","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"07","key":"ref56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/2048872616650869","article-title":"Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials","volume":"6","author":"G Ducrocq","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"02","key":"ref57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"F J Neumann","year":"2019","journal-title":"Eur Heart J"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1725190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T18:42:09Z","timestamp":1633545729000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1725190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,6]]},"published-print":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1725190","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]}}}